BioXcel Therapeutics (BTAI) News Today $3.11 -0.28 (-8.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.15 +0.04 (+1.29%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period BioXcel Therapeutics price target raised to $4 from $2 at MizuhoSeptember 12 at 11:39 AM | msn.comBioXcel reports results from SERENITY At-Home Pivotal Phase 3 safety trialSeptember 10 at 10:36 PM | msn.comBioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)September 10 at 7:00 PM | seekingalpha.comBioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In StudySeptember 10 at 5:35 PM | msn.comBioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or ...September 10 at 5:35 PM | finance.yahoo.comBioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or SchizophreniaSeptember 10 at 6:30 AM | globenewswire.comCanaccord Genuity Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)September 9, 2025 | theglobeandmail.comMurchinson Ltd. Buys Shares of 136,076 BioXcel Therapeutics, Inc. $BTAISeptember 8, 2025 | marketbeat.comBioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | markets.businessinsider.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Expands By 472.5%September 4, 2025 | marketbeat.comBioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Rises By 472.5%September 4, 2025 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Receives "Buy" Rating from HC WainwrightAugust 30, 2025 | marketbeat.comBioXcel Therapeutics (NASDAQ:BTAI) Downgraded to Hold Rating by Zacks ResearchAugust 30, 2025 | marketbeat.comBioXcel Therapeutics announces SERENITY Phase 3 trial met primary endpointAugust 28, 2025 | msn.comBioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret LaterAugust 28, 2025 | msn.comBioXcel to seek approval for at-home use of agitation drug after upbeat studyAugust 27, 2025 | reuters.comBioXcel whipsaws after late-stage trial win for lead assetAugust 27, 2025 | msn.comBioXcel shares rise on positive Phase 3 safety trial resultsAugust 27, 2025 | msn.comUPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®August 27, 2025 | globenewswire.comBioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or ...August 27, 2025 | markets.businessinsider.comBioXcel Sparks Retail Frenzy As Stock Soars Ahead Of Phase 3 Results For Bipolar, Schizophrenia DrugAugust 27, 2025 | msn.comBioXcel's agitation drug meets main goal in at-home studyAugust 27, 2025 | msn.comBioXcel to seek at-home approval for agitation drug after upbeat studyAugust 27, 2025 | reuters.comBioXcel stock climbs after positive Phase 3 safety trial resultsAugust 27, 2025 | za.investing.comBioXcel Therapeutics Reports Successful Results from SERENITY At-Home Trial for BXCL501 as At-Home Treatment for Agitation in Bipolar Disorders and SchizophreniaAugust 27, 2025 | quiverquant.comQBioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®August 27, 2025 | globenewswire.comBioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025August 26, 2025 | globenewswire.comBioxcel Therapeutics Files Prospectus for $80M Share SaleAugust 21, 2025 | theglobeandmail.comBioxcel Therapeutics (BTAI) Receives a Buy from Canaccord GenuityAugust 20, 2025 | theglobeandmail.comBioXcel Therapeutics announces pre-sNDA meeting responses from FDAAugust 19, 2025 | msn.comBioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaAugust 19, 2025 | globenewswire.comBioXcel stock surges after positive FDA feedback on BXCL501 expansionAugust 18, 2025 | investing.comBioXcel Shares Jump After Encouraging FDA Feedback on BXCL501 Home-Use ExpansionAugust 18, 2025 | msn.comBioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or SchizophreniaAugust 18, 2025 | globenewswire.comBioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label (This works)August 18, 2025 | msn.comBioXcel Therapeutics price target raised to $10 from $8 at H.C. WainwrightAugust 15, 2025 | msn.comBioXcel Therapeutics Receives Positive FDA FeedbackAugust 15, 2025 | msn.comBioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” SeriesAugust 13, 2025 | globenewswire.comBioXcel Therapeutics Raises $30.4M, Meets Financing CovenantAugust 12, 2025 | theglobeandmail.comBioXcel Therapeutics trading resumesAugust 12, 2025 | msn.comBioXcel Therapeutics trading halted, volatility trading pauseAugust 12, 2025 | msn.comBioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business UpdatesAugust 12, 2025 | globenewswire.comBioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth ConferenceAugust 11, 2025 | globenewswire.comMizuho Securities Keeps Their Hold Rating on Bioxcel Therapeutics (BTAI)August 9, 2025 | theglobeandmail.comBioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in ...August 6, 2025 | finance.yahoo.comBioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical StudiesAugust 6, 2025 | globenewswire.comBioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaAugust 1, 2025 | globenewswire.comBioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®July 21, 2025 | globenewswire.comBioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial ProgressJuly 11, 2025 | insidermonkey.com Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BTAI Media Mentions By Week BTAI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼0.880.93▲Average Medical News Sentiment BTAI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼102▲BTAI Articles Average Week Get the Latest News and Ratings for BTAI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for BioXcel Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Prima BioMed News Annexon News Voyager Therapeutics News Lyell Immunopharma News Alpha Teknova News Tonix Pharmaceuticals News Sagimet Biosciences News AC Immune News Aclaris Therapeutics News Humacyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
